ReviewPeerJ2024
The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target.
Review in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Omega-3 pretreatment attenuates hepatic inflammatory histopathology in LPS-Induced rat endotoxemia: exploratory SIRT1/HO-1 findings.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Ligustrazine attenuates high-fat diet-induced neurobehavioral deficits and hepatic dysfunction via modulation of the HO-1/Nrf-2/SIRT-1/PPAR-α axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Decoding the effect of Diceratella elliptica on the oxidative stress-Inflammation axis in hyperthyroid-induced hepatotoxicity.Journal, genetic engineering & biotechnology · 2025Article
- Modulation of SIRT-1, NF-κB/TNF-α/IL-6, and ERK/Caspase-3 by Lutein Mitigates Methotrexate-Induced Hepatotoxicity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effects of Lacticaseibacillus rhamnosus LB1.5 as potential probiotic supplement on the liver and adipose tissue of adult male mice to a high-fat diet.Molecular and cellular biochemistry · 2025Article
- Article
- Quercetin as an Anti-Diabetic Agent in Rodents-Is It Worth Testing in Humans?International journal of molecular sciences · 2025Review
- Pyridostigmine Mitigates Methotrexate-Induced Liver Fibrosis in Rats: Association with Changes in BMP-9, SIRT1, and Endoglin Expression.Biomedicines · 2025Article
- Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sotagliflozin Modulation of SIRT1/Nrf2 and PI3K/AKT Signaling Pathway Ameliorates Experimental Liver Fibrosis in Rats.Oxidative medicine and cellular longevity · 2025Article
- Plant-Derived Natural Product-Based Nanoformulations for Healthcare Application.Nanotheranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Liver disease is a common and serious threat to human health. The progression of liver diseases is influenced by many physiologic processes, including oxidative stress, inflammation, bile acid metabolism, and autophagy. Various factors lead to the dysfunction of these processes and basing on the different pathogeny, pathology, clinical manifestation, and pathogenesis, liver diseases are grouped into different categories. Specifically, Sirtuin1 (SIRT1), a member of the sirtuin protein family, has been extensively studied in the context of liver injury in recent years and are confirmed the significant role in liver disease. SIRT1 has been found to play a critical role in regulating key processes in liver injury. Further, SIRT1 seems to cause divers outcomes in different types of liver diseases. Recent studies have showed some therapeutic strategies involving modulating SIRT1, which may bring a novel therapeutic target. To elucidate the mechanisms underlying the role of sirtuin1 in liver injury and its potentiality as a therapeutic target, this review outlines the key signaling pathways associated with sirtuin1 and liver injury, and discusses recent advances in therapeutic strategies targeting sirtuin1 in liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.